PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.
Epistemonikos ID: 29fb01b86bfa0aa93d9cdf3242a09ea65a3edffd
First added on: May 13, 2024